Stockreport

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Immunovant, Inc.  (IMVT) 
PDF NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with au [Read more]